drugset

drugset / Trial / NCT02310048

Comparative Oral Bioavailability Study of MT-1303

NCT02310048 ↗

Phase 1 Completed 34 enrolled Tanabe Pharma Corporation

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the comparative oral bioavailability of a Formulation B versus the Formulation A of MT-1303.

Timeline

Start: 2014-11
Primary completion: 2015-03
Completion: 2015-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	amiselimod	Small molecule	—	Oral

Indications